Bio-Solutions Corp Begins Production of the Type2 Defense™. Pursuing $25 Billion plus Type II and Pre-Diabetic Marketplace
SAN ANTONIO, July 30, 2012 /PRNewswire/ -- (OTCQB: BISU) (PINKSHEETS: BISU) Bio-Solutions Corp is pleased to announce that the company has started production of the recently acquired Type2 Defense™. Type2 Defense™ is an Antioxidant and glucose control dietary supplement powder. This proprietary formula is packaged with 30 packets to a box. The product powder drink mix delivery system has been developed to support healthy glucose levels for type 2 diabetics and pre-diabetics. From a "Target Market" perspective, management believes this to be a very lucrative market place that has a built in clientele here domestically in North America to drive sales and revenues. Type2 Defense™ has been scheduled for Market entry by September 2012. "We will be completing the first production run of Type2 Defense™ very soon. We are excited about our new product, which will be sold and marketed primarily on the internet, further company developments, forthcoming," stated newly appointed CEO Bill Gallagher.
There is an Estimated 100 plus Million Americans at risk of diabetes in the following order: Data from the 2011 National Diabetes Fact Sheet (released Jan. 26, 2011) Total prevalence of diabetes Total: 25.8 million children and adults in the United States -- 8.3% of the population -- have diabetes. Diagnosed: 18.8 million people Undiagnosed: 7.0 million people Pre-diabetes: 79 million people
New Cases: 1.9 million new cases of diabetes are diagnosed in people aged 20 years and older in 2010.
In contrast to the 2007 National Diabetes Fact Sheet, which used fasting glucose data to estimate undiagnosed diabetes and pre-diabetes, the 2011 National Diabetes Fact Sheet uses both fasting glucose and A1C levels to derive estimates for undiagnosed diabetes and pre-diabetes. These tests were chosen because they are most frequently used in clinical practice.
Given the two types of Diabetes (Type 1 and Type 2), Type2 Defense(TM) will obviously cater to Type 2 patients, which are 90-95%, of all diabetics. Type2 Defense(TM) will help maintain healthy blood glucose levels to combat complications of Diabetes which include: high blood
Operations will be managed in San Antonio. Research and development is managed by Ex Nestles SA nutritional food chief scientist Sekhar Mallangi. Product fulfillment will be handled by Lou Bellino, one of Americas top web product fulfillment operators, marketing will be driven by the talented San Antonio based marketing firm BOSS Creative for the company's new upcoming website development. Search engine optimization (SEO) management, video product description and newsletters.
According to Dailyfinance.com (1/27/11 Big Pharma Article), "In 2009, the U.S. diabetes market grew 17% from 2008, reaching $14.9 billion, according to data from health care information company IMS Health. Worldwide, the market generated sales of over $25 Billion, according to independent business information provider Vision again. By 2019, Morningstar projects the worldwide diabetes market, excluding insulin, will grow to over $55 billion."
We believe that there is a growing market place that lacks adequate healthy tools to maintain healthy blood glucose levels. Type2 Defense(TM) is a powder blend of natural ingredients that has been developed to help support healthy blood glucose levels. The Type2 Defense(TM) powder blend is a flavorful supplement when mixed with water becomes an effective vehicle that encourages sustainable healthy habits. A convenient and all natural pure health beverage containing green tea blended with cinnamon and blueberry flavors and the Type2 Defense(TM) proprietary blend. The Product's goal is to provide a safe and natural supplement that will assist in the stabilization of healthy glucose levels along with providing strong antioxidants.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Bio-Solutions actual results to differ materially from those in the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law.
Investor Contact & Public Relations
SOURCE Bio-Solutions Corp